MedPath

Evaluation of Study Experiences of Neuroendocrine Tumor Patients

Not yet recruiting
Conditions
Neuroendocrine Tumors
Registration Number
NCT05967481
Lead Sponsor
Power Life Sciences Inc.
Brief Summary

Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This research will admit a wide range of data on the clinical study experience of neuroendocrine tumor patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with neuroendocrine tumor.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Patient is at least 18 years of age
  • Diagnosis of neuroendocrine tumor
  • Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
  • Enrolled in another research study
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or lactating woman

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of neuroendocrine tumor patients who remain in clinical trial until completion12 months
Rate of patients who decide to join in a neuroendocrine tumor clinical research3 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Power Life Sciences

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

Power Life Sciences
πŸ‡ΊπŸ‡ΈSan Francisco, California, United States
Michael B Gill
Contact
415-900-4227
https://www.withpower.com/contact-us@withpower.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.